ASCO 2018 bladder and kidney cancer highlights

A variety of highlighly anticipated urological oncology research with great potential was shown at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL. Here, Neal Shore, MD, of Carolina Urologic Research Center, Myrtle Beach, SC, discusses the bladder and kindey cancer work that he was most excited about. Dr Shore highlights work targeting the FGFR pathway (BLC2001; NCT02365597) and Nectin-4 (EV-101; NCT02091999) in urothelial carcinoma. For renal cancer, he highlights the combination of nivolumab plus ipilimumab in the first-line setting, as well as tyrosine kinase inhibitor selection.